Literature DB >> 3826468

Hepatitis B virus transmission in a public school: effects of mentally retarded HBsAG carrier students.

C A Williams, F T Weber, M McKim, C I Steadham, M A Kane.   

Abstract

In 1980, 18 institutionalized children, carriers of hepatitis B virus (HBV), were enrolled into two special education schools, and staff and students were monitored for HBV markers. Eleven HBV exposures were observed and those exposed were given hepatitis B immune globulin. After 3.5 years, no remaining staff showed serological evidence of HBV infection but three of 61 susceptible students did so. The three students probably acquired the infection outside the school. At the conclusion of the project, one school located in the community decided not to institute a vaccine program for students or staff. The other school, located inside the mental retardation institution, established an organized vaccine initiative. Indications for use of hepatitis vaccine in schools should be individualized to accommodate for differences in student and staff interaction, physical design of the school, and number and behaviors of HBsAg carrier students.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3826468      PMCID: PMC1646926          DOI: 10.2105/ajph.77.4.476

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  14 in total

1.  Distribution and characteristics of hepatitis B surface antigen in body fluids of institutionalized children and adults.

Authors:  M L Tiku; K R Beutner; R I Ramirez; J L Dienstag; H A Sultz; P L Ogra
Journal:  J Infect Dis       Date:  1976-10       Impact factor: 5.226

2.  Hepatitis B transmitted by a human bite.

Authors:  M B MacQuarrie; B Forghani; D A Wolochow
Journal:  JAMA       Date:  1974-11-04       Impact factor: 56.272

3.  Development and distribution of hemagglutinating antibody against the hepatitis B antigen in institutionalized populations.

Authors:  W Szmuness; A M Prince; G F Etling; R Pick
Journal:  J Infect Dis       Date:  1972-11       Impact factor: 5.226

Review 4.  Transmission of hepatitis B virus.

Authors:  D P Francis; M S Favero; J E Maynard
Journal:  Semin Liver Dis       Date:  1981-02       Impact factor: 6.115

5.  Transmission of hepatitis B virus to classroom contacts of mentally retarded carriers.

Authors:  B Breuer; S M Friedman; E S Millner; M A Kane; R H Snyder; J E Maynard
Journal:  JAMA       Date:  1985-12-13       Impact factor: 56.272

6.  Viral hepatitis B: aspects of environmental control.

Authors:  W W Bond; N J Petersen; M S Favero
Journal:  Health Lab Sci       Date:  1977-10

7.  An institutional outbreak of hepatitis B related to a human biting carrier.

Authors:  T P Cancio-Bello; M de Medina; J Shorey; M D Valledor; E R Schiff
Journal:  J Infect Dis       Date:  1982-11       Impact factor: 5.226

8.  Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis.

Authors:  A G Mulley; M D Silverstein; J L Dienstag
Journal:  N Engl J Med       Date:  1982-09-09       Impact factor: 91.245

9.  Deinstitutionalized mentally retarded hepatitis-B surface antigen carriers in public school classes: a descriptive study.

Authors:  C W Bakal; J S Marr; L F Novick; E S Millner; W D Goldman; O E Pitkin
Journal:  Am J Public Health       Date:  1980-07       Impact factor: 9.308

10.  Mentally retarded hepatitis-B surface antigen carriers in NYC public school classes: a public health dilemma.

Authors:  C W Bakal; L F Novick; J S Marr; E S Millner; W D Goldman; O Pitkin
Journal:  Am J Public Health       Date:  1980-07       Impact factor: 9.308

View more
  2 in total

1.  Prevalence of hepatitis B infection in long-stay mentally handicapped adults.

Authors:  F Asensio; J M Bayas; M J Bertran; M A Asenjo
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

2.  Hepatitis B infection in a day school for mentally retarded students: transmission from students to staff.

Authors:  R S Remis; M A Rossignol; M A Kane
Journal:  Am J Public Health       Date:  1987-09       Impact factor: 9.308

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.